Treatment of Metastatic Malignant Melanoma with Dacarbazine plus Tamoxifen

New England Journal of Medicine

Volumn 327, Issue 8, 1992, Pages 516-523

  Cocconi, Giorgio ^a   Bella, Mariangela ^a   Calabresi, Federico ^b   Tonato, Maurizio ^c   Canaletti, Rodolfo ^e   Boni, Corrado ^a   Buzzi, Franco ^d   Ceci, Guido ^a   Corgna, Enrichetta ^c   Costa, Paolo ^f   Lottici, Renata ^a   Papadia, Franco ^f   Sofra, Maria Carla ^b   Bacchi, Marisa ^a  

^a MAGGIORE HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c POLICLINICO MONTELUCE   (Italy)

^d S MARIA HOSPITAL   (Italy)

^e Ospedale Civile ^*  (United States)

^f UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; ESTROGEN RECEPTOR; TAMOXIFEN;

ADOLESCENT; ADULT; AGED; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONFERENCE PAPER; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; COMPARATIVE STUDY; DACARBAZINE; FEMALE; HUMAN; MALE; MELANOMA; MENOPAUSE; MIDDLE AGE; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE; TAMOXIFEN;

EID: 0026625695     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199208203270803     Document Type: Article

References (58)

1. Legha SS. Current therapy for malignant melanoma. Semin Oncol 1989; 16: Suppl 1: 34–44.
2. Mc Clay EF, Mastrangelo MJ. Systemic chemotherapy for metastatic melanoma. Semin Oncol 1988; 15: 569–77.
3. National Cancer Institute of Canada Melanoma Group. Vinblastine, bleomycin, and cis-platinum for the treatment of metastatic malignant melanoma. J Clin Oncol 1984; 2: 131–4.
4. Luikart SD, Kennealey GT, Kirkwood JM. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 1984; 2: 164–8.
5. Nesbit RA, Woods RL, Tattersall MHN, et al. Tamoxifen in malignant melanoma. N Engl J Med 1979; 301: 1241–2.
6. Karakousis CP, Lopez RE, Bhakoo HS, Rosen F, Moore R, Carlson M. Estrogen and progesterone receptors and tamoxifen in malignant melanoma. Cancer Treat Rep 1980; 64: 819–27.
7. Meyskens FL Jr, Voakes JB. Tamoxifen in metastatic malignant melanoma. Cancer Treat Rep 1980; 64: 171–3.
8. Fisher RI, Neifeld JP, Lippman ME. Oestrogen receptors in human malignant melanoma. Lancet 1976; 2: 337–9.
9. Walker MJ, Beattie CW, Patel MK, Ronan SM, Das Gupta TK. Estrogen receptor in malignant melanoma. J Clin Oncol 1987; 5: 1256–61.
10. Tormey DC, Falkson G, Crowley J, Falkson HC, Voelkel J, Davis TE. Dibromodulcitol and adriamycin +/- tamoxifen in advanced breast cancer. Am J Clin Oncol 1982; 5: 33–9.
11. Mouridsen HT, Rose C, Engelsman E, Sylvester R, Rotmensz N. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer: a randomized study of CMF vs CMF plus tamoxifen. Eur J Cancer Clin Oncol 1985; 21: 291–9.
12. Viladiu P, Alonso MC, Avella A, et al. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients: a randomized trial. Cancer 1985; 56: 2745–50.
13. Cocconi G, De Lisi V, Boni C, et al. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer: a prospective randomized study. Cancer 1983; 51: 581–8.
14. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81.
16. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1–39.
17. SAS user's guide: statistics, version 5 ed. Cary, N.C.: SAS Institute, 1985.
18. Ceci G, Bella M, Melissari M, Gabrielli M, Bocchi P, Cocconi G. Fatal hepatic vascular toxicity of DTIC: is it really a rare event? Cancer 1988; 61: 1988–91.
19. Folkerd EJ, James VHT. Aromatization of steroids in peripheral tissues. J Steroid Biochem 1983; 19: 687–90.
20. Deslypere JP, Verdonck L, Vermeulen A. Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Metab 1985; 61: 564–70.
21. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984; 68: 1403–5.
22. McClay EF, Mastrangelo MJ, Bellet RE, Berd D. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 1987; 71: 465–9.
23. McClay EF, Mastrangelo MJ, Sprandio JD, Bellet RE, Berd D. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989; 63: 1292–5.
24. Berd D, McLaughlin CJ, Hart E, et al. Short course, high-dose tamoxifen (TAM) with cytotoxic chemotherapy for metastatic melanoma. Proc Am Soc Clin Oncol 1991; 10: 291. abstract.
25. Creagan ET, Ingle JN, Woods JE, Pritchard DJ, Jiang NS. Estrogen receptors in patients with malignant melanoma. Cancer 1980; 46: 1785–6.
26. Zava DT, Goldhirsch A. Estrogen receptor in malignant melanoma: fact or artefact? Eur J Cancer Clin Oncol 1983; 19: 1151–9.
27. Benassayag C, Vallette G, Hassid J, Raymond JP, Nunez EA. Potentiation of estradiol binding to human tissue proteins by unsaturated nonesterified fatty acids. Endocrinology 1986; 118: 1–7.
28. McCarty KS Jr, Szabo E, Flowers JL, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986; 46: Suppl: 4244s–4248s.
29. Feucht KA, Walker MJ, Das Gupta TK, Beattie CW. Effect of 17β-estradiol on the growth of estrogen receptor-positive human melanoma in vitro and in athymic mice. Cancer Res 1988; 48: 7093–101.
30. Balch CM, Soong S-j, Shaw HM, et al. Changing trends in the clinical and pathologic features of melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-j, eds. Cutaneous melanoma. 2nd ed. Philadelphia: J.B. Lippincott, 1991:40–5.
31. Balch CM, Soong S-j, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1: 126–34.
32. Adami H-O, Bergström R, Holmberg L, Klareskog L, Persson I, Pontén J. The effect of female sex hormones on cancer survival. JAMA 1990; 263: 2189–93.
33. Luster MI, Boorman GA, Dean JH, et al. Immunological alterations in mice following adult exposure to diethylstilbestrol. In: Dean JH, Padarathsingh ML, eds. Biological relevance of immunosuppression. New York: Van Nostrand, 1981:153.
34. Kalland T. Alterations of antibody response in female mice after neonatal exposure to diethylstilbestrol. J Immunol 1980; 124: 194–8.
35. Paavonen T, Andersson LC, Adlercreutz H. Sex hormone regulation of in vitro immune response: estradiol enhances human B cell maturation via inhibition of suppressor T cells in pokeweed mitogen-stimulated cultures. J Exp Med 1981; 154: 1935–45.
36. Hanna N, Schneider M. Enhancement of tumor metastasis and suppression of natural killer cell activity by β-estradiol treatment. J Immunol 1983; 130: 974–80.
37. Hrushesky WJM, Gruber SA, Sothern RB, et al. Natural killer cell activity: age, estrous- and circadian-stage dependence and inverse correlation with metastatic potential. J Natl Cancer Inst 1988; 80: 1232–7.
38. Fioretti MC. Immunopharmacology of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC). Pharmacol Res Commun 1975; 7: 481–91.
39. Bonmassar A, Frati L, Fioretti MC, Romani L, Giampietri A, Goldin A. Changes of the immunogenic properties of K36 lymphoma treated in vivo with 5(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC). Eur J Cancer 1979; 15: 933–9.
40. Marelli O, Franco P, Canti G, et al. DTIC xenogenized lines obtained from an L1210 clone: clonal analysis of cytotoxic T lymphocyte reactivity. Br J Cancer 1988; 58: 171–5.
41. Gulino A, Santoni A, Screpanti I, Frati L. Antitumoral antiestrogen stimulates natural killer (NK) activity in C3H mouse. J Leuk Biol 1985; 38: 159. abstract.
42. Mandeville R, Ghali SS, Chausseau JP. In vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen). Eur J Cancer Clin Oncol 1984; 20: 983–5.
43. Hersey P, Hobbs A, Edwards A, McCarthy WH, McGovern VJ. Relationship between natural killer cell activity and histological features of lymphocyte infiltration and partial regression of the primary tumor in melanoma patients. Cancer Res 1982; 42: 363–8.
44. Parmiani G, Anichini A, Fossati G. Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J Natl Cancer Inst 1990; 82: 361–70.
45. Cohen JHM, Danel L, Cordier G, Saez S, Revillard JP. Sex steroid receptors in peripheral T cells: absence of androgen receptors and restriction of estrogen receptors to OKT8-positive cells. J Immunol 1983; 131: 2767–71.
46. Blatt J, Rotenstein D, Dienes S. Cytotoxicity of tamoxifen for acute lymphoblastic leukaemia in vitro. Br J Cancer 1984; 50: 837–9.
47. Blatt J, Rotenstein D, Cole D, Wolfson A. Inhibition of neuroblastoma (NB) by tamoxifen (TAM) in combination with estradiol (E). Proc Am Soc Clin Oncol 1984; 3: 77. abstract.
48. Walker MJ. Role of hormones and growth factors in melanomas. Semin Oncol 1988; 15: 512–23.
49. Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor-β: biological function and chemical structure. Science 1986; 233: 532–4.
50. Derynck R, Jarrett JA, Chen EY, et al. Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature 1985; 316: 701–5.
51. Kehrl JH, Wakefield LM, Roberts AB, et al. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986; 163: 1037–50.
52. Behl C, Weilbach F, Apfel R, Wilhelm J, Dürr G, Bogdahn U. Melanoma inhibiting activity (MIA) — biological characterization of a neuroectodermal derived tumor growth inhibitor. Proc Am Assoc Cancer Res 1990; 31: 59. abstract.
53. De Larco JE, Pigott DA, Lazarus JA. Ectopic peptides released by a human melanoma cell line that modulate the transformed phenotype. Proc Natl Acad Sci U S A 1985; 82: 5015–9.
54. Roberts AB, Wakefield LM, Sporn MB. Loss of negative growth control by transforming growth factor-β in malignancy: mechanism and clinical implications. Adv Clin Oncol 1990; 1: 283–90.
55. Wieland I, Muller G, Braun S, Birchmeier W. Reversion of the transformed phenotype of B16 mouse melanoma: involvement of an 83 kd cell surface glycoprotein in specific growth inhibition. Cell 1986; 47: 675–85.
56. Brown TJ, Lioubin MN, Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes: synergistic antiproliferative activity of transforming growth factor β1, interferon-γ, and oncostatin M for human melanoma cells. J Immunol 1987; 139: 2977–83.
57. Knabbe C, Lippman ME, Wakefield LM, et al. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417–28.
58. Colletta AA, Wakefield LM, Howell FV, et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990; 62: 405–9.